– USA, NV – THC Therapeutics (OTC: THCT) today announced the appointment of Parker Mitchell to its Board of Directors as CEO, effective immediately.
Brandon Romanek, the Founder of THC Therapeutics, will assume the position of Chairman of the Board of Directors.
“I am excited and blessed to welcome Mr. Mitchell to the team; he’s an exceptional talent in the realm of publicly traded companies and will serve THCT to the best of his abilities. My transition to Chairman could not be more welcome. I will continue to provide oversight for the development of THCT, anticipated deal flow, raising capital, and leveraging Mr. Mitchell’s talent to expand opportunities for the company.” said Board chairman, Brandon Romanek.
About Parker Mitchell
Mr. Mitchell is an alumnus of The State University of New York at Buffalo and has been working with public companies for the better part of the last decade. Over the last five years, Mr. Mitchell has helped publicly traded companies by putting their company’s story and opportunities in front of the investing public. Mr. Mitchell has helped raise over a hundred million dollars for publicly traded companies over the last five years. Through his niche business experience and relationships with hedge funds and high-net-worth investors, he intends to do the same for THCT.
Mr. Mitchell said, “I am honored for the opportunity to be CEO of THC Therapeutics; I will work every day to bring the dHydronator to market and generate revenue as this is the most important goal of my job as CEO. By bringing our patented technology to the market we hope to cement THCT as a competitive publicly traded cannabis company. These steps should be a tremendous driver for shareholder value. Brandon Romanek and I will continue to expand the management team, and board of directors, as we forward our vision of advancing health and wellness for all. This is only the beginning.”
Mr. Mitchell added, “I plan to build on the tremendous amount of work the company has already completed on the dHydronator and bring the final steps of commercialization to fruition. Mr. Romanek has done a great job since he took the company public via a reverse merger three years ago. The accomplishments of the past 36 months have brought the company to the point of expansion where more talent is needed. In addition to the dHydronator, I will pursue investors, partnerships, and acquisitions to strengthen our position in the market. For these reasons, I believe THCT is an extremely undervalued company, and I’m excited to see where a little push can take us.”
About THC Therapeutics
THC Therapeutics, Inc. is focused on developing its patented dHydronator, a sanitizing herb dryer. The main function of the dHydronator is to greatly accelerate the drying time of cannabis while sanitizing it. The dHydronator can be used to dry a variety of herbs; it has been specifically tested for use with cannabis, and it can reduce the drying time for cannabis from 10-14 days to less than 14 hours. The Company may also focus some of its future operations on participation in cannabis-testing lab facilities and developing personal wellness centers. The Company is seeking partnerships in the Cannabis & Health/Wellness industries in the United States & Canada.
For more information: https://thct.io/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
